FDA Schedules Gene Therapy Meeting for July 30
Published Date: 7/24/2026
Notice
Summary
The FDA is updating the meeting details for a big discussion about a new medicine called Vusolimogene Oderparepvec from Replimune, Inc. This meeting, happening on July 30, 2026, lets the public watch online and even speak up during a special time slot. Patients, doctors, and medicine makers should pay attention because this could affect new treatment options and future healthcare costs.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14984, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Prognostic Test for Assessment of Chronic Kidney Disease Progression
The FDA is officially putting a special kidney disease test into Class II, meaning it’s safe and effective but with some extra rules to keep it that way. This change helps patients get access to this cool new test faster by cutting down red tape. The new classification is effective July 24, 2026, and could save companies time and money while making sure the test works well.
2026-15021, Evonik Corporation, Filing of Food Additive Petition (Animal Use)
Evonik Corporation has asked the FDA to approve ethyl cellulose as a safe binder and coating for amino acids in food for ruminant animals like cows and sheep. This change could improve animal feed quality without extra costs or delays, with the petition officially filed on June 16, 2026. Farmers and feed producers should keep an eye out as this could soon become part of the rules.
2026-14986, Medical Devices; General Hospital and Personal Use Devices; Classification of the Diabetes Digital Behavioral Therapeutic Device
The FDA has officially placed the diabetes digital behavioral therapeutic device into Class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification took effect on July 24, 2026, with benefits starting from July 7, 2023, making it easier and potentially cheaper for makers to bring these devices to market.
2026-14985, Medical Devices; Immunology and Microbiology Devices; Classification of the Over-the-Counter Test To Detect SARS-CoV-2 From Clinical Specimens
The FDA is officially putting over-the-counter COVID-19 tests into a safer, easier-to-manage category called Class II, starting July 24, 2026. This change helps make sure these tests work well and are safe, while also making it simpler for companies to bring new tests to you. If you’re a test maker or a user, expect better access and less red tape, with no extra costs announced.
Previous / Next Documents
Previous: 2026-15016, Cellular, Tissue, and Gene Therapies Advisory Committee; Amendment of Notice-Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells)
The FDA updated the meeting details for the Cellular, Tissue, and Gene Therapies Advisory Committee reviewing Capricor, Inc.'s Deramiocel treatment. The meeting now happens on July 29, 2026, with options to join in person or online, and public talks scheduled midday. This change helps everyone stay in the loop about this important cell therapy review without any cost or deadline shifts.
Next: 2026-15020, Environmental Impact Statements; Notice of Availability
The EPA just shared new Environmental Impact Statements (EIS) for big projects like power lines, highways, and ports that could affect communities and nature. People and groups have until mid to late August or September 2026 to review and comment, so their voices can shape these projects. These updates help keep projects safe, smart, and eco-friendly without surprise costs or delays.